Quick Facts

Regions:
Where the impacts of the investment may be experienced.
  • Middle East and North Africa
Banks:
International, regional and national development finance institutions. Many of these banks have a public interest mission, such as poverty reduction.
  • European Bank for Reconstruction and Development (EBRD)
Status: Active
Bank Risk Rating: B
Risk rating varies among banks and may refer only to the particular investment and not to the risk for the project as a whole. Projects marked 'U' have an 'Unknown' risk rating at the time of disclosure.
Board Decision Date: 2016-05-25
The estimate day the bank will vote on a proposed investment. The decision dates may change, so review updated project documents or contact the EWS team.
Borrower or Client: MS Pharma Partners Holding W.L.L.
The holder of the loan, grant, or other investment.
Sectors:
The service or industry focus of the investment. A project can have several sectors.
  • Industry and Trade
Investment Amount (USD): $ 50.00 million
Value listed on project documents at time of disclosure. If necessary, converted to USD$. Please review updated project documents for more information.
Project Cost (USD): $ 50.00 million
Value listed on project documents at time of disclosure. If necessary, converted to USD$. Please see updated project documentation for more information.

Share This Page

 

Contact Us

Do you have more information on
this project, or want to get involved?
Contact EWS

Primary Source

Original disclosure @ EBRD website
Updated in EWS: 2018-01-02
Disclosure Date: 2016-09-09
MS Pharma Equity
EBRD-47793

Project Description
PROJECT DESCRIPTION A USD 50 million equity investment in MS Pharma Partners Holding W.L.L., a subsidiary of MS Pharma Ventures Holdings W.L.L., a manufacturer of generic pharmaceuticals operating in the MENA region. PROJECT OBJECTIVES The investment will support MS Pharma's expansion in the region, including the acquisition of a brownfield pharmaceutical plant in Turkey, purchase of files for the development and commercialisation of new generic pharmaceutical products, and working capital to support itsoperations in Jordan. The investment will enable MS Pharma to increase its capacity, diversify its revenues and accelerate the entry into new markets.
Investment Description
Contact Information
Yazan Abu Abboudyazan. abu-abboud@mspharma.com +962 6 5827999 www.mspharma.com P.O Box 142904 Amman 11844 Jordan ACCOUNTABILITY MECHANISM OF EBRD The Project Complaint Mechanism (PCM) is the independent complaint mechanism and fact-finding body for people who have been or are likely to be adversely affected by an European Bank for Reconstruction and Development (EBRD)-financed project. If you submit a complaint to the PCM, it may assess compliance with EBRD's own policies and procedures to prevent harm to the environment or communities or it may assist you in resolving the problem that led to the complaint through a dialogue with those implementing the project. Additionally, the PCM has the authority to recommend a project be suspended in the event that harm is imminent. You can contact the PCM at pcm@ebrd.com or you can submit a complaint online using an online form, http://www.ebrd.com/eform/pcm/complaint_form?language=en. You can learn more about the PCM and how to file a complaint at http://www.ebrd.com/work-with-us/project-finance/project-complaint-mechanism.html.
Bank Documents